Personal Finance
GS

Why Intercept Pharmaceuticals Stock Is Moving Higher Today

3-D animation of a human body with the liver highlighted in red.

What happened

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) rose by as much as 17% on above-average volume Monday. The spark?

The drugmaker's shares were responding positively to back-to-back upgrades from analysts at Goldman Sachs and Wedbush on Monday. For instance, Goldman's Salveen Richter upgraded Intercept's shares from a sell to a buy rating, and hiked the firm's 12-month price target from $46 to $157 a share. Wedbush, on the other hand, doled out a $217 price target on the stock Monday morning. Wedbush's noteworthy price target implies a monstrous 126% upside potential from where Intercept's shares closed last week.

3-D animation of a human body with the liver highlighted in red.

Image Source: Getty Images.

As of 2:46 p.m. EDT on Monday, Intercept's shares were still up by a healthy 16.8% following these dual upgrades.

So what

Analysts have been changing their tune toward Intercept of late, thanks to the rising sales of the company's primary biliary cholangitis drug Ocaliva. The big deal is that this liver disease drug racked up an impressive $43.2 million in sales in the second quarter, beating consensus sales estimates by nearly $3 million in the process.

Prior to this beat, Wall Street was overtly skeptical about Ocaliva's commercial prospects due to the deaths of 19 patients late last year. These fatalities caused the Food and Drug Administration to issue a dreaded black-box warning about the drug's dosing regimen. This revised label, however, hasn't had a discernible impact on the drug's sales so far -- evinced by Ocaliva's stellar Q2 performance.

Now what

Intercept appears set to continue heading higher for the foreseeable future for two reasons. First, the fear over Ocaliva's stricter label is clearly starting to dissipate. Second, the drug's late-stage trial for nonalcoholic steatohepatitis is on track to produce top-line results in the first half of 2019. If successful, Ocaliva could gain an all-important first-mover advantage for this high-value indication. As such, investors on the hunt for above-average growth opportunities may want to grab some shares of this promising biotech stock right now.

10 stocks we like better than Intercept Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Intercept Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GS ICPT

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More